Drug Trial Radar · NCT03989310
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Dec 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 1, 2019
Primary completion
May 31, 2021
Study completion Mar 31, 2022
Sponsor
- Lead sponsor
- Chinese PLA General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 18, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The outcome of pancreatic cancer is extremely poor. NCCN guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen, but the response rate is unacceptably low. PD-1 blockade has been developed to a new class of cancer immunotherapy that could restore an adequate immunosurveillance against the neoplasm and enhance T-cell-mediated anticancer immune responses. Manganese has been confirmed to activate antigen-presenting cells and function as mucosal immunoadjuvants in pre-clinical studies. This one-arm, phase I/II study is designed to assess the safety and efficacy of Manganese primed combined therapy of anti-PD-1 antibody and chemotherapy.
Conditions
- Pancreatic Cancer
Interventions
Manganese ChlorideDrug
Administered by inhalation at 0.4mg/kg twice per week in a 3-week cycle
nab-paclitaxelDrug
Administered intravenously, 200mg/d on day 1 and day 8 in a 3-week cycle
GemcitabineDrug
Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
anti-PD-1 antibodyDrug
Administered intravenously, 2-4mg/kg on day 2 in a 3-week cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects with treatment-related adverse events (AEs)Time frame: 12 months
- Disease control rate (DCR)Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Biotherapeutic Department of Chinese PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.